SCHEMBL19933445

SCHEMBL19933445

Bc1nc(C(=O)NCC(=O)O)c(O)c(B)c1-c1cc(Cl)ccc1C

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 20/20 0.59
VEGFA P15692 2/20 0.59
FLT1 P17948 2/20 0.59
BBOX1 O75936 3/20 0.46
FTO Q9C0B1 2/20 0.46
EGLN3 Q9H6Z9 3/20 0.42
THRA P10827 2/20 0.41
THRB P10828 2/20 0.41
ASPH Q12797 2/20 0.40
KDM8 Q8N371 2/20 0.40
TET3 O43151 1/20 0.40
TET2 Q6N021 1/20 0.40
OGFOD1 Q8N543 1/20 0.40
TET1 Q8NFU7 1/20 0.40
HIF1AN Q9NWT6 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19933528 0.83 EGLN1 (0.68) EGLN1VEGFAFLT1BBOX1EGLN3
SCHEMBL19933506 0.83 VEGFA (0.39) EGLN1VEGFAFLT1
SCHEMBL19933448 0.82 EGLN1 (0.67) EGLN1VEGFAFLT1BBOX1FTO
SCHEMBL19933384 0.80 EGLN1 (0.57) EGLN1VEGFAFLT1BBOX1FTO
SCHEMBL19933380 0.76 EGLN1 (0.49) EGLN1BBOX1FTOTHRATHRB
SCHEMBL19933409 0.75 EGLN1 (0.48) EGLN1BBOX1FTOEGLN3THRA
SCHEMBL1921504 0.74 EGLN1 (1.00) EGLN1VEGFAFLT1BBOX1FTO
SCHEMBL1218880 0.72 EGLN1 (0.67) EGLN1VEGFAFLT1BBOX1FTO
SCHEMBL12900998 0.71 EGLN1 (0.57) EGLN1VEGFAFLT1EGLN3THRB
SCHEMBL19933385 0.71 EGLN1 (0.58) EGLN1VEGFAFLT1BBOX1FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS AKEBIA THERAPEUTICS, INC. (US) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180065933-A1 DEUTERIUM-ENRICHED HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE ENZYME INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN1 6/4885VEGFA 286/4885FLT1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.